Search Results

Innovative Medicine

June 24, 2018

Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications

June 8, 2018

New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association’s 78th Annual Scientific Sessions

Innovative Medicine

October 2, 2017

Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program

Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes

Innovative Medicine

May 24, 2016

U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes

In a Phase 3 study of patients not previously treated with any diabetes medication, combination therapy with canagliflozin and metformin lowered blood sugar more than either medicine alone

Medical technologies

March 4, 2013

FDA Clears First Blood Glucose Monitoring System To Automatically Send Results Wirelessly Via Bluetooth® Technology to iOS Devices

OneTouch® Verio®Sync Meter With Mobile App Allows Patients To Easily View and Share Blood Sugar Information Using Their iPhone®, iPad® or iPod touch®

Corporate

November 20, 2015

Janssen Submits INVOKAMET® XR (Canagliflozin / Metformin Hydrochloride Extended Release) for Approval by the U.S. FDA as an Adjunctive Treatment in Adults with Type 2 Diabetes

Innovative Medicine

September 21, 2016

U.S. FDA Approves INVOKAMET® XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes

Newest INVOKANA® (canagliflozin) plus metformin treatment provides unique formulation option for first-line therapy

Innovative Medicine

May 5, 2017

Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists

Patients Taking INVOKANA® 300 mg Were Significantly Less Likely to Discontinue the Medication or Be Prescribed a New Antihyperglycemic Agent

Innovative Medicine

August 2, 2017

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

Innovative Medicine

November 14, 2017

INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

Search Results

No Results

Recently Viewed

Search Results